Bluebird Bio Raises $30 Million Series C To Accelerate Pipeline Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Gene therapy biotech hopes to move lead program for childhood cerebral adrenoleukodystrophy into a registrational trial later this year.
You may also be interested in...
Financings Of The Fortnight: Bluebird Spots Brighter Skies For Gene Therapy Investment
Plus news on recent financings by California Institute for Regenerative Medicine, Alimera Sciences, Durata Therapeutics and CoDa Therapeutics.
Bluebird Bio Raises $60M Series D Round To Treat Rare Diseases
The gene therapy start-up taps diversified public and private investors, as well as strategic backer Shire, for one of the year’s biggest rounds of private capital funding for a biotech thus far.
EU's CHMP Clears Europe's First Gene Therapy, UniQure's Glybera
After three previous negative votes, the Netherlands biotech uniQure gains the first positive opinion from the Committee for Medicinal Products for Human Use for a gene therapy in Europe. Glybera is used to treat the ultra-rare condition lipoprotein lipase deficiency.